Previous close | 262.00 |
Open | 263.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 263.00 - 263.00 |
52-week range | 243.42 - 354.00 |
Volume | |
Avg. volume | 203 |
Market cap | 195.015B |
Beta (5Y monthly) | 0.15 |
PE ratio (TTM) | 16.76 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 10.86 (4.15%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Adaptimmune's (ADAP) shares plummet as the company;s collaboration to develop and commercialize allogeneic cell therapies with Roche gets terminated.
Roche's (RHHBY) Columvi, in combination with GemOx, achieves the primary endpoint of overall survival in a late-stage lymphoma study.
ALX Oncology (ALXO) announces positive results from an early to mid-stage study of an investigational combination regimen to treat indolent and aggressive R/R B-NHL.